2024 ISFM and AAFP Consensus Guidelines on Long-Term NSAID Use in Cats — Evidence Summary

Bottom line

• The 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats (Taylor et al., J Feline Med Surg 2024) provide the current authoritative framework for NSAID prescribing in cats, addressing mechanism of action, indications, pre-prescription screening, comorbidity management (especially CKD), efficacy monitoring, and adverse effect management.¹
• Robenacoxib and meloxicam are identified as the most widely studied NSAIDs in cats, with evidence supporting their use in chronic pain management including in cats with stable, early chronic kidney disease.¹
• The guidelines highlight the cat's unique metabolism (reduced glucuronyl transferase capacity) as a key species consideration, and emphasize the potential for drug interactions with concurrently prescribed medications.¹
• Chronic pain may be challenging to detect in cats; comorbidities — particularly CKD — are common in senior cats and complicate NSAID prescribing decisions.¹
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Guideline overview

Taylor S, Gruen M, KuKanich K, Lascelles BDX, Monteiro BP, Sampietro LR, Robertson S, Steagall PV. "2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats." J Feline Med Surg 2024; 26(4):1098612X241241951. PMID 38587872. Produced by an expert panel convened jointly by ISFM and AAFP; information is based on available literature, expert opinion, and panel members' clinical experience.

Key guideline domains

Mechanism of action and feline-specific pharmacology

NSAIDs inhibit COX isoenzymes, reducing prostaglandin synthesis and thereby attenuating pain and inflammation. The guidelines note that the cat's limited glucuronyl transferase activity — the primary phase II conjugation pathway for many drugs in other species — is a key species consideration affecting NSAID choice, dosing, and interval.^1,2 Drugs that rely heavily on glucuronidation for elimination (such as aspirin and some non-selective NSAIDs) accumulate to toxic levels in cats; robenacoxib's predominant biliary excretion pathway partially mitigates this concern, though NSAID risk is never eliminated in this species.

Pre-prescription screening

Before initiating long-term NSAID therapy in cats, the guidelines support a pre-treatment baseline evaluation including renal function (creatinine, SDMA, urine specific gravity, urine protein:creatinine ratio if indicated), hepatic parameters, blood pressure measurement, and a thorough history for concurrent medications.¹ These baselines enable detection of pre-existing comorbidities that modify risk, and establish the reference values against which monitoring results will be interpreted.

CKD and NSAID use: the core clinical challenge

Chronic kidney disease affects a significant proportion of cats over 7 years of age, and many feline DJD patients are older cats at elevated CKD risk. The guidelines acknowledge that the intersection of CKD and chronic pain management is the most challenging NSAID prescribing scenario in cats.¹ Their position: robenacoxib and meloxicam have evidence of safety in cats with stable, early (IRIS Stage 1–2) CKD, and can be used with appropriate monitoring, owner education, and dose optimization. NSAIDs should be used cautiously in cats with IRIS Stage 3 CKD and avoided in Stage 4 or in the presence of acute kidney injury, decompensation, or uncontrolled hypertension.¹

Drug interactions

The guidelines flag the potential for NSAID interactions with concurrently prescribed medications as an underappreciated risk in clinical practice.¹ NSAIDs + ACE inhibitors or ARBs can impair renal autoregulation. NSAIDs + corticosteroids increase GI ulceration risk. NSAIDs + furosemide may reduce diuretic efficacy and increase renal risk. These interactions are particularly relevant in senior cats with multi-morbidity.

Monitoring during long-term use

The guidelines recommend periodic monitoring of renal function, blood pressure, and clinical response during long-term NSAID therapy.¹ Interval recommendations are individualized to patient risk: more frequent early in treatment (e.g., 4 weeks after initiation), and then every 3–6 months in stable patients. Owner-reported outcome measures — feeding behavior changes, grooming, mobility, demeanor — should be elicited at each contact and ideally structured using validated tools (e.g., CSOM, Feline Musculoskeletal Pain Index).

Adverse effect management

Adverse effects of NSAIDs in cats include GI signs (vomiting, inappetence, diarrhea), renal effects (creatinine increase, azotemia), and — rarely — hepatic effects. The guidelines recommend stopping NSAID therapy immediately if GI signs, acute illness, anorexia, dehydration, or acute worsening of renal values occurs, and not reinstating without a fresh risk-benefit assessment.¹

Clinical takeaways

These guidelines represent a modern, evidence-grounded departure from historical veterinary caution around any NSAID use in cats. The nuanced position — long-term NSAID use is feasible in selected cats with appropriate monitoring, including some CKD patients — gives practitioners a defensible framework. For individual patients, the decision matrix should include: DJD severity and quality-of-life impact, CKD stage and trajectory, concurrent medications, owner monitoring reliability, and availability of alternative analgesics (such as frunevetmab) where NSAID risk is high.

A specific patient requiring long-term NSAID management?

Get an instant cited answer — no signup needed for your first question.

Try Voyage Clinical Desk

References

1. Taylor S, Gruen M, KuKanich K, et al. 2024. 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats. J Feline Med Surg 26(4):1098612X241241951. https://europepmc.org/articles/PMC11103309
2. Sparkes AH, Heiene R, Lascelles BD, et al. 2010. ISFM and AAFP consensus guidelines: long-term use of NSAIDs in cats. J Feline Med Surg 12(7):521-538. https://europepmc.org/articles/PMC11148988

Changelog

• 2026-06-23: First published.

---

For licensed veterinary professionals. Evidence summary, not clinical advice. Voyage is decision support, not a substitute for clinical judgment — always confirm dosing and treatment with current formularies and your own clinical judgment.